Biotech Values

[tony111]

The best way to the market for 380 should have been in the neoadjuvant setting in inflammatory and locally advanced breast cancer. Perjecta didn't even have survival data and was granted approval based on pathology response. 380 should be combined with herceptin+Perjecta+chemo in the neoadjuvant setting as the the combo hits all the resistance pathway. It won't be a large trial and won't take long to obtain the pathology response.